Brenca Monica, Maestro Roberta
a Experimental Oncology 1 , CRO Aviano National Cancer Institute , Aviano , PN 33081 , Italy.
Expert Rev Anticancer Ther. 2015;15(12):1473-88. doi: 10.1586/14737140.2015.1108192. Epub 2015 Nov 4.
Sarcomas are an aggressive and highly heterogeneous group of mesenchymal malignancies with different morphologies and clinical behavior. Current therapeutic strategies remain unsatisfactory. Cytogenetic and molecular characterization of these tumors is resulting in the breakdown of the classical histopathological categories into molecular subgroups that better define sarcoma pathobiology and pave the way to more precise diagnostic criteria and novel therapeutic opportunities. The purpose of this short review is to summarize the state-of-the-art on the exploitation of massive parallel sequencing technologies, also known as next generation sequencing, in the elucidation of sarcoma pathobiology and to discuss how these applications may impact on diagnosis, prognosis and therapy of these tumors.
肉瘤是一组具有侵袭性且高度异质性的间充质恶性肿瘤，具有不同的形态和临床行为。目前的治疗策略仍不尽人意。这些肿瘤的细胞遗传学和分子特征正在导致经典组织病理学分类细分为分子亚组，这些亚组能更好地定义肉瘤的病理生物学，并为更精确的诊断标准和新的治疗机会铺平道路。这篇简短综述的目的是总结在阐明肉瘤病理生物学方面利用大规模平行测序技术（也称为下一代测序）的最新进展，并讨论这些应用如何可能影响这些肿瘤的诊断、预后和治疗。
